ASCO 2023

Sonia trial: How does the new data change clinical practice - or does it at all? Insights from Italy, United States and Germany.

CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe

ADC revolution: How can the new results be integrated in clinical practice? Which studies are in sight and which ones do we need in the future?

Discussions and controversies on social-media: what is the impact of science-twitter discussions on the everyday practice in oncology?

CDK4/6 inhibitors in EBC: Amazing data, but longer follow up needed!

Expanding CDK4/6i therapy in EBC: How to select patients for the right therapy?

PART1: How to de-escalate chemotherapy? What is the best strategy to identify patients who don´t need chemotherapy?

PART2: Trying to understand optimal therapy for pre-menopausal women - promising results, but still long way to go!

Chemotherapy de-escalation in HER2+ patients: Consequences of the PHERGain data on daily practice?!

Data from Meta-Analyses of almost 15k Patients: Who benefits from ovarian function suppression?

New data on Ribocilib in adjuvant setting EBC: What does it change immediately, what changes are expected in the future? Perspectives from Europe and Northern America

Palbociclib after Palbociclib might not be the best option

TILs are prognostic but not predictive in HER2+ EBC

Ribociclib has arrived in the adjuvant setting

PHERGain opens the possibility to avoid chemotherapy in HER2+ breast cancer

Another proof of efficacy of immunotherapy in advanced TNBC

Ovarian function - Ovarian suppression not necessary in young patients?

First data with adjuvant ribociclib

TILs in HER2+ disease - prognostic, but not enough to deescalate

TILs subtypes are associated with clinical features and prognosis in HR+/HER2- BC

Early follow-up shows clear benefit

From PENELOPE-B to SURVIVE

Chemo-immunotherapeutic signals especially in HER2low possibly predictive of chemotherapy response in EBC

1/3 of patients with HER2+ in future without chemotherapy?

Ribociclib improves iDFS

Discussions on CDK4/6 inhibitors in EBC

10 years update on ShortHER

My EBC highlights from ASCO23

More CDK4/6 options for EBC patients

Tumor-informed ctDNA likely prognostic for relapse in ER positive and HER2 negative EBC

Young patients benefit from ovarian suppression

White blood cells with increasing prognostic relevance? Data from the GeparNuevo Study

Checkpoint inhibition in endometrial cancer: new therapy algorithms needed

Can we preserve our patients form chemotherapy?

Response adapted, chemotherapy-free option in HER2+ EBC

Analyses of ctDNA in PENELOPE-B: Test methods are increasingly accurate

A challenge for clinical management

Practice changing or not quite yet?

SOC of ovarian ablation confirmed in meta-analysis.

De-escalation of CT for early BC

Kolejny dowód na skuteczność immunoterapii w zaawansowanym raku trójujemnym

Tumor-informed ctDNA wahrscheinlich prognostisch für einen Rückfall beim ER positive und HER2 negative eBC

NATALEE nicht überraschend aber überzeugend positiv

1/3 der Patientinnen mit HER2+ zukünftig ohne Chemotherapie?

TILs sind prognostisch aber nicht prädiktiv beim HER2+ eBC

Ovar Funktion - Ovarielle Supression verzichtbar bei jungen Patientinnen?

Czy wystarczy, aby zmienić standardy?

Palbociclib después de Palbociclib podría no ser la mejor opción

Eine Herausforderung für viele Patienten, wenig Doktoren

SOC der ovarialen Ablation in der Metaanalyse bestätigt

TILs w rakach HER2+ - znaczenie rokownicze, ale nie droga do deeskalacji leczenia

Eine Herausforderung für das klinische Management

Primele date cu ribociclib adjuvant

Response adaptierte, Chemotherapie-freie Option beim HER2+ eBC

TILs Subtypen sind assoziiert mit klinischen Merkmalen und Prognose beim HR+/HER2- BC

PHERGain abre la posibilidad de evitar la quimioterapia en el cáncer de mama HER2+

I miei punti salienti di ASCO23

Von PENELOPE-B zur SURVIVE

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen der Chemotherapie

E-Health Applications in Oral Cancer Therapy

What is the optimal therapie sequence for HR+ MBC patients?

The start of precision medicine in HR+ breast cancer

Updates on ADCs in metastatic breast cancer

Molecular imaging for endocrine responsivness

Continued OS benefit for Sacituzumab Govitecan

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

Mises à jour sur les ADC dans le cancer du sein métastatique

Aggiornamenti sugli ADC nel carcinoma mammario metastatico

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo studio PALMIRA

CDK4/6 Sequencing? ESR-1 not ready for prime time? Palbo rechallenge?

CDK4/6i in first line and beyond & Biomarkers

The value of eHealth

Update ADC efficacy

Confirming results for PARPi in mCRPC

Over-staging of bone scan compared with PSMA PET/CT

LuPARP combination study: LuPSMA and Olaparib in mCRPC

ARASEC: ADT + Daralutamide for mHSPC

Part2: Important update on testosterone-recovery

AI for prediction in local prostate carcinoma

PRL-02: Intramuscular arbiraterone

Part 1: Important update on testosterone-recovery

TALAPRO-2: Results and controversies

DEAR trial: real-world comparator analyses of ARIs

Metastasis-directed for prostate cancer

PSA nadir 6 month after Radiotherapy is strong prognostic marker for survival

PEACE 1 - results and controversies

PAPR-inhibitors: Patient-selection matters!

Intensified or de-intensified therapy in mHSPC

Reassuring real-world data!

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

PSA nadir 6 månader efter radioterapi är en prognostisk markör för överlevnad

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Intensifierad eller de-intensifierad behandling vid mHSPC?

PARP-inhibitors: La selección de pacientes es importante

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

What is your preferred sequence in 1st line treatment and how you treat after progress?

Triple therapy in mCSPC - which is the ideal partner for radiotherapy? And which patients should received irradiation?

PARPi in PCa: more genetic testing is required as PRO data demand better patient selection

The beginning of a new era in urothelial cancer?!

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Q-TWiST in the therapy of aUC

New SoC option for metastatic bladder cancer

Targeted therapies in advanced urothelial cancer: The renaissance?!

Extent of lymphadenectomy in cystectomy

Enfortumab vedotin + pembrolizumab 1stL in cisplatin-ineligible patients

New standard for MIBC

FGFR inhibition

First line in cisplatin-ineligible advance urothelial cancer: It´s getting busy out there

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El renacimiento?!

Primera línea en cáncer urotelial avanzado no elegible para cisplatina: Hay mucho trabajo ahí fuera

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Nouvelles options de soins standard pour le cancer de la vessie métastatique

The efficacy of FGFR targeting

The efficacy of neo-adjuvant therapy (ddMVAC, Cisplatinum)

Update EV/Pembro, Avelumab Maintenance

Long term follow up in advanced renal cell cancer: Is everything clear, yet?

The impact of microbiome and supplements on therapy efficacy

Primary endpoint not reached: what do we learn from CONTACT-03 results?

Non ccRCC: how should we treat patients today?

Long-term follow-up for IO/TKI in mRCC

IO rechallenge in mRCC

New standard for 2nd line RCC?

Update and take home message of 1st Line mRCC

New data non ccRCC

1st Line therapy RCC: which combination to choose?

Lenvatinib + pembrolizumab in non-clear cell renal cell carcinoma

News from the adjuvant

ADAURA: Osimertinib improves survival in the treatment of EGFRm rNSCLC

The value of perioperative chemo-IO in rNSCLC and the importance of staging

Adjuvant and neoadjuvant strategies in resectable NSCLC

Which should we prefer: neoadjuvant, adjuvant or perioperative chemo/IO?

A chemo-free preop. IO strategy?

More options in the perioperative setting

Adjuvant IO in KRASm patients

Perioperative treatment

Role of periopertative IO confirmed

An imperfect analysis, but perfect results

A new standard of care for operated patients with eGFRmut adenocarcinoma

A new standard of care

EGFR testing necessary in the adjuvant setting

CheckMate 9LA: 4‑year clinical update

ADAURA - results and controversies

ADAURA - Discussion closed?

Another neoadjuvant chemo/IO option

Induction options in the perioperative setting

Confirmation of neoadjuvant immunotherapy

OS benefit from EGFR receptor TKI

Added benefit of perioperative chemo/IO in stage 2-3b NSCLC

Un nouveau standard therapeutique pour les patients opérés d’un adenocarcinome EGFR muté

Rolle der periopertativen IO bestätigt

Más opciones en el entorno perioperatorio

Stratégies adjuvantes et néoadjuvantes dans le CBNPC résécable

Que devrions-nous préférer: traitement néoadjuvant, adjuvant ou chimio/IO périopératoire?

Toegevoegde waarde van periperatief chemo-immuno bij stadium II-IIIB NSCLC

ADAURA- discussie gesloten?

TTF-treatment requires further studies

Sotorasib: clear clinical benefit, but short follow-up time

Does ADC + chemo + IO replace the existing concepts?

Pembro + chemo in pts with TKI-resistant EGFRm / Sunvozertinib - a drug for Exon20 insertions

Zorifertinib: an option when osimertinib is not available

Update on KRASG12Cm treatment options - how to proceed?

CORRELATE - a real world analysis

ADC + ICI ± Pt-CT in patients with aNSCLC

TROP2-ADC shows high response rates in 1L-combination therapy, but safety must be observed

IO in EGRF positive patients post TKI

Stopping treatment is ok

LUNAR: TTF medical device shows OS-benefit, but more information needed

Hyperfractionation - an interestingh concept, but not for every patient

New data from another BiTE

More BiTEs, more possibilities

Can we incoporate biomarkers in SCLC treatment?

Treatment strategies in SCLC

A positive trial with no impact

Hyperfractionated radiotherapy for SCLC

Más BiTEs, más posibilidades

Stratégies de traitement dans le SCLC

Kunnen we biomarkers gebruiken om behandeling te selecteren voor SCLC?

Immune checkpoint inhibitors in malignant mesothelioma

ONCOalert (inclusive patient advocates) consensus on the results of the PROspect trial

No practice-changing data in mesothelioma, other studies to await

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom